Targeting Glutaminase Isoforms GLS and GLS2 in Luminal Breast Cancer

Area of Science:

• Biochemistry
• Oncology
• Molecular Biology

Background:

• Glutaminase activity fuels tumor cell proliferation and is linked to poor outcomes in breast cancer.
• The glutaminase inhibitor CB-839 shows promise for triple-negative breast cancer.
• Estrogen Receptor-positive (ER+) breast cancer requires distinct therapeutic targets.

Purpose of the Study:

• To investigate the role of glutaminase (GLS and GLS2) in ER+ breast cancer.
• To evaluate CB-839 as a therapeutic agent in ER+ breast cancer.
• To identify potential therapeutic targets for ER+ breast cancer subtypes.

Main Methods:

• In vitro studies using ER+ luminal breast cancer cell lines.
• siRNA-mediated knockdown of glutaminase genes (GLS and GLS2).
• Assessment of cell proliferation, apoptosis, and cell cycle progression.
• Inhibition of glutaminase activity using CB-839.

Main Results:

• Silencing GLS significantly reduced proliferation and induced apoptosis in luminal breast cancer cells.
• Silencing GLS2 reduced proliferation in luminal B cells but did not affect apoptosis or cell cycle.
• CB-839 showed minimal impact on ER+ breast cancer cell growth.
• Glutaminase is essential for ER+ breast cancer growth and survival.

Conclusions:

• Glutaminase plays a vital role in the growth and survival of ER+ breast cancer.
• Co-targeting GLS and GLS2 presents a potential novel therapeutic strategy for ER+ breast cancer.
• Further research into the molecular mechanisms is warranted.